By-health(SZ:300146)2025-04-25 10:50Financial Performance - The company's revenue for Q1 2025 was ¥1,791,668,420.41, a decrease of 32.29% compared to ¥2,646,096,290.74 in the same period last year[5] - Net profit attributable to shareholders was ¥454,532,555.26, down 37.44% from ¥726,556,175.48 year-on-year[5] - The total operating revenue for Q1 2025 was ¥1,791,668,420.41, a decrease of approximately 32.3% compared to ¥2,646,096,290.74 in the same period last year[35] - The net profit for the current period is CNY 466,605,072.83, a decrease of 35.1% compared to CNY 718,954,041.77 in the previous period[36] - Operating profit for the current period is CNY 592,062,895.03, down 33.5% from CNY 890,074,030.88 in the previous period[36] - Total revenue from operating activities is CNY 1,503,834,321.72, compared to CNY 1,910,972,503.80 in the previous period, reflecting a decline of 21.4%[39] - The total comprehensive income attributable to the parent company is CNY 461,693,233.81, compared to CNY 635,069,874.78 in the previous period, a decrease of 27.3%[37] Cash Flow and Assets - The net cash flow from operating activities increased by 142.40% to ¥362,171,910.84, compared to ¥149,410,014.22 in the previous year[5] - The net cash flow from investment activities was 66.27 million RMB, a significant improvement of 139.32% compared to a net outflow of 168.55 million RMB in the previous period[18] - The cash flow from operating activities shows a net increase of CNY 362,171,910.84, significantly up from CNY 149,410,014.22 in the previous period[40] - Investment activities generated a net cash flow of CNY 66,270,226.91, recovering from a negative cash flow of CNY -168,546,498.60 in the previous period[40] - The total assets at the end of the reporting period were ¥14,014,558,492.86, a decrease of 1.86% from ¥14,279,753,758.79 at the end of the previous year[5] - The total current assets were ¥7,415,981,956.92, down from ¥7,614,632,771.01 at the beginning of the period, representing a decrease of about 2.6%[27] - The company’s cash and cash equivalents were ¥2,457,987,212.24, down from ¥2,596,956,308.44, which is a decline of approximately 5.4%[27] Expenses and Costs - The total operating costs for Q1 2025 amounted to ¥1,250,081,454.05, down from ¥1,778,396,686.70 in the previous year, reflecting a reduction of about 29.5%[35] - The operating cost specifically for goods sold was ¥561,428,005.84, which decreased from ¥796,403,183.64, indicating a decline of approximately 29.6%[35] - The company incurred sales expenses of CNY 542,703,011.84, a decrease of 34.3% from CNY 825,583,947.02 in the previous period[36] - Research and development expenses decreased by 30.49% to ¥21,827,831.69, attributed to adjustments in project timelines[14] - The research and development expenses amounted to CNY 21,827,831.69, down from CNY 31,402,437.53, indicating a reduction of 30.6%[36] Shareholder Information - The company repurchased a total of 888,000 shares, accounting for 0.0522% of the total share capital, with a total payment of approximately 9.99 million RMB[23] - The total number of ordinary shareholders at the end of the reporting period was 74,920, with the largest shareholder holding 41.78% of the shares[19] - The company has invalidated 1.9 million shares of reserved restricted stock due to not meeting performance targets and employee departures[24] - The initial grant price for the 2024 restricted stock incentive plan was adjusted from ¥7.70 to ¥7.34 per share[24] Brand Performance - The main brand "汤臣倍健" generated revenue of 983 million RMB, a decline of 36.37% year-over-year[22] - The "健力多" brand saw revenue drop to 201 million RMB, a decrease of 46.15% year-over-year[22] - Online channel revenue was 766 million RMB, down 15.78% year-over-year, while offline channel revenue fell to 988 million RMB, a decline of 42.62%[22] Future Outlook - The company aims to enhance operational quality and focus on core product innovation and digital transformation in 2025[21]